MHRA Field Safety Notices August 2026: UK Medical Device Alerts Issued

• The MHRA issued several Field Safety Notices (FSNs) between August 24 and August 28, 2026, concerning various medical devices.
• Affected products include femoral head/stem prosthesis adaptors, respiratory pathogen nucleic acid tests, urostomy bags, anaesthesia workstations, and patient monitors.
• Infusion pump cassettes, neonatal/adult intensive care ventilators, and interventional fluoroscopic X-Ray systems were also subject to these safety alerts.
• Recipients of FSNs from manufacturers are legally required to act on them, while the MHRA publishes these notices for informational purposes.
• Lawyers and compliance officers must actively monitor these notices to avoid regulatory non-compliance, product liability, and reputational damage.

Failure to promptly act on an FSN can lead to significant regulatory non-compliance, exposing organizations to potential penalties and sanctions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a series of Field Safety Notices (FSNs) between August 24 and August 28, 2026, highlighting potential safety concerns with various medical devices. These MHRA Field Safety Notices August 2026 cover a broad spectrum of healthcare products, underscoring the continuous need for vigilance within the medical device sector across the United Kingdom. The agency's role is to publish these notices for informational purposes, ensuring that relevant parties are aware of the alerts.

Among the devices subject to these UK medical device alerts are femoral head/stem prosthesis adaptors, identified by MHRA references 40647164 (2026/008/026/601/112) and 40655224 (2026/008/027/601/106). Respiratory pathogen nucleic acid tests, specifically multiple-type variants including PNplus models RFIT-ASY-0143 (30 pack) and RFIT-ASY-0142 (6 pack), and JI models RFIT-ASY-0138 (30 pack) and RFIT-ASY-0135 (6 pack)ASY-0104, are also affected, with MHRA reference 40610695 (2026/008/021/601/024).

Other critical devices include one-piece open-ended urostomy bags (MHRA references 40647867 and 40622243, 2026/008/020/601/010), anaesthesia workstations (MHRA reference 40657877, 2026/008/020/601/010), and centralized patient monitors (MHRA references 40633163, 2026/008/021/601/056, and 40607245, 2026/008/020/601/092, including models MP00310 and MP00311). Infusion pump cassettes (MHRA reference 40630462, 2026/008/025/601/011, August 2026 ref FA1479) and neonatal/adult intensive care ventilators (MHRA references 40558257, 2025/005/021/601/034, and 40607869, 2026/008/021/601/093) are also part of this recent series of warnings. Furthermore, several models of interventional fluoroscopic X-Ray systems, such as 718075, 718094, 718095, 718130, 718131, 718132, 718400, 718096, 718133, 718401, 718076, 718134, 50796090, 50796120, and 50796150, are included under MHRA references 40653768 (2026/008/025/601/127), 40607506 (2026/008/012/601/131), 40632523, and 40644810 (2026/008/021/601/069).

The MHRA, as the primary regulatory body for medical devices in the UK, emphasizes that while it publishes these Field Safety Notices for public awareness, the onus to act lies squarely with the recipients. Any entity receiving an FSN directly from a manufacturer is legally obligated to take appropriate action without delay. This directive is a cornerstone of GB medical product safety and healthcare compliance UK, ensuring that potential risks associated with medical devices are addressed promptly and effectively.

For any specific inquiries or clarifications regarding a particular Medical device recall warnings UK, the MHRA advises contacting the issuing manufacturer directly. The agency's role is to facilitate the dissemination of critical safety information, not to provide detailed guidance on individual product issues. This clear delineation of responsibility is crucial for maintaining an efficient and responsive regulatory environment.

To support ongoing monitoring and compliance efforts, the MHRA maintains an accessible archive of past notices. Stakeholders can view FSNs published since January 2020 and November 2014 directly through the agency's platforms. For even older records, predating November 2014, the National Archives website serves as the official repository, providing a comprehensive historical record of MHRA FSN list 2026 and prior alerts.

For legal professionals and compliance officers advising medical device manufacturers, distributors, or healthcare providers in the UK, actively monitoring these MHRA Field Safety Notices is not merely good practice but a critical component of risk management. The frequent issuance of notices, such as the MHRA FSN list 2026, highlights the dynamic nature of medical device safety and the continuous need for vigilance across the supply chain and in clinical settings. These Medicines and Healthcare products Regulatory Agency notices serve as early warnings that demand immediate attention.

Failure to promptly act on an FSN can lead to significant regulatory non-compliance, exposing organizations to potential penalties and sanctions. Beyond regulatory repercussions, inaction can also result in substantial product liability exposure, particularly if a device defect or safety issue leads to patient harm. Such incidents can severely damage an organization's reputation, erode public trust, and incur considerable financial costs through litigation and corrective measures.

Therefore, a robust internal process for reviewing affected products and implementing corrective actions in response to every FSN is indispensable. This proactive approach not only mitigates legal and financial risks but also reinforces a commitment to patient safety and adherence to the stringent standards governing GB medical product safety. The consistent flow of these alerts underscores the importance of embedding FSN review into routine compliance protocols.

Lawyers and compliance officers advising medical device manufacturers, distributors, or healthcare providers in the UK must actively monitor these MHRA Field Safety Notices. Failure to promptly act on an FSN can result in significant regulatory non-compliance, potential product liability exposure, and reputational damage, necessitating immediate review of affected products and implementation of corrective actions.

Source: Original reporting via GOV.UK